Results 161 to 170 of about 335,877 (277)

Barriers and enablers for publishing results of randomized trials: a cross-sectional survey of principal investigators in sub-Saharan Africa. [PDF]

Res Integr Peer Rev
Hohlfeld A, Kredo T, Clarke M.
europepmc   +1 more source

Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension

Arthritis &Rheumatology, Accepted Article.
Objectives To evaluate the impact of bimekizumab, a dual IL‐17A and IL‐17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr‐axSpA) and 2 (r‐axSpA) and their open‐label extension (OLE).
Walter P. Maksymowych, Sofia Ramiro, Denis Poddubnyy, Xenofon Baraliakos, Robert G.W. Lambert, Ute Massow, Tom Vaux, Chetan Prajapati, Alexander Marten, Natasha de Peyrecave, Mikkel Østergaard   +10 more
wiley   +1 more source

Comments on: 'The Impact of Gratitude Combined with Relaxation Therapy on Anxiety Reduction in Breast Cancer Patients Undergoing Chemotherapy: A Comparative Study'. [PDF]

Indian J Palliat Care
Thakur S, Aggarwal A.
europepmc   +1 more source

MDL‐800‐induced SIRT6 activation decreases age‐associated osteoarthritis in mice

Arthritis &Rheumatology, Accepted Article.
Objective SIRT6 is a nuclear‐localized histone deacetylase that regulates multiple pathways associated with aging. This study aimed to determine whether systemic administration of a small molecule activator of SIRT6, MDL‐800, decreases the severity of age‐associated osteoarthritis (OA) in mice.
Matheus Moreira Perez, Pranay Ramteke, Bahiyah Watson, Owen Haslam, Eirene Choi, Susan Chubinskaya, Mandy J. Peffers, William R. Davis, Jacqueline Shine, Brian O. Diekman, Richard F. Loeser, Theresa A. Freeman, Makarand V. Risbud, John A. Collins   +13 more
wiley   +1 more source

Alarming bradycardia in a patient with Dengue fever [PDF]

Al Ameen Journal of Medical Sciences, 2016
I.A. Khan, Altaf Ahmed, Sha Ruknuddin, Zahid Ahmed   +3 more
doaj  

Trajectory analysis in clinical research. [PDF]

Clin Kidney J
D'Arrigo G, Gori M, Chesnaye NC, Jager KJ, Dekker FW, van Diepen M, Zoccali C, Tripepi G.   +7 more
europepmc   +1 more source

Associating cognitive abilities with naturalistic search behavior

Journal of the Association for Information Science and Technology, Volume 76, Issue 4, Page 665-685, April 2025.
Abstract Differences in cognitive abilities affect search behaviors, but this has mostly been observed in laboratory experiments. There is limited research on how users search for information in real‐world, naturalistic settings and how real‐world search behaviors relate to cognitive abilities.
Tung Vuong, Pritom Kumar Das, Tuukka Ruotsalo   +2 more
wiley   +1 more source

Principal Component‐Based Classification of Blazar Candidates of Uncertain Type in the 4FGL/LAT

Astronomische Nachrichten, EarlyView.
ABSTRACT We adopted principal component analysis (PCA), linear discriminant analysis (LDA), and support vector machines (SVM), to study classification for a sample of 2708 Fermi blazars: 1142 BL Lac objects (BLLs), 759 flat spectrum radio quasars (FSRQs), and 807 blazar candidates of uncertain type (BCUs).
Wen‐Xin Yang, Guo‐Hai Chen, Jing‐Tian Zhu, Hong‐Guang Wang, Denis Bastieri, Xu‐Hong Ye, Jing‐Chao Liang, De‐Xiang Wu, Jiang‐He Yang, Anton A. Strigachev, Rumen S. Bachev, Jun‐Jie Feng, Yi Liu, Jun‐Hui Fan   +13 more
wiley   +1 more source

Impact of delayed medical consultation on dengue severity and mortality during the 2023 outbreak in Burkina Faso. [PDF]

IJID Reg
Ouedraogo D, Diendere EA, Ky/Ba A, Kabore R, Ouédraogo S, Diallo I, Ouedraogo/Sondo A.   +6 more
europepmc   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source